RELEASE DATE:  July 18, 2002

PA NUMBER:  PAR-02-130 (This PA has been reissued, see PAR-05-149)

EXPIRATION DATE:  July 30, 2005, unless reissued. 

National Institute of Neurological Disorders and Stroke (NINDS) 
National Institute on Deafness and Other Communication Disorders(NIDCD) 
National Institute on Drug Abuse (NIDA)  
o Purpose of the PA
o Research Objectives
o Mechanism(s) of Support 
o Funds Available
o Eligible Institutions
o Individuals Eligible to Become Principal Investigators
o Special Requirements
o Where to Send Inquiries
o Submitting an Application
o Peer Review Process
o Review Criteria
o Award Criteria
o Required Federal Citations
The National Institute of Neurological Disorders and Stroke (NINDS), 
the National Institute on Deafness and Other Communication Disorders 
(NIDCD) and the National Institute on Drug Abuse (NIDA) are committed 
to expanding neuroscience research opportunities for faculty, students 
and fellows at minority institutions.  Data taken from the National 
Academy of Sciences Report (2000) entitled "Addressing the Nation's 
Changing Needs for Biomedical and Behavioral Scientists" demonstrates 
that the proportion of racial/ethnic minorities receiving scientific 
graduate degrees is not representative of the general population.  
Moreover, a survey from the Association of Neuroscience Departments and 
Programs (2000) demonstrated that only 8% of tenure-track faculty were 
minorities. To address this issue, the NINDS and NIDA Strategic Plans 
on Minority Health Disparities and the NIDCD aim to enhance research 
capacity building and training among minority institutions.

The purpose of the Collaborative Neurological Sciences (CNS) Award is 
to encourage collaborative research investigations among scientists at 
minority institutions and grantees from leading research laboratories 
that have NIH or equivalent grant support to conduct neuroscience 
research.  It is envisioned that funding from the CNS Award will lead 
to joint research efforts and publications, shared research 
instrumentation and resources, exchange of research techniques, and 
other scientific activities to enhance the research capabilities of 
applicants at minority institutions to successfully compete for 
independent research funding during the performance period of award.  
The nature and scope of these scientific interactions should promote 
better opportunities to educate and prepare students and fellows for 
productive research careers in neuroscience.

1) General characteristics of the CNS Award Program:  The CNS award 
will support an investigator-initiated research project in which the 
applicant and collaborating neuroscientist(s) work in a clearly defined 
area of mutual research interest.  The intent of the award is to 
develop competitive neuroscience research programs at minority 
institutions leading to successful competition for traditional research 
project grants (e.g., R-series and/or equivalent NSF grants) by the 
applicant investigator during the performance period of the award.  The 
project should consist of a thematic research plan that involves an 
efficacious collaborative effort among the participating investigators, 
each of whom will be conducting a portion of the total research project 
in his/her own laboratory.  Examples of the collaborative interactions 
include the sharing of ideas, data, and exchanging of research 
techniques and expertise.  It is anticipated that interactions between 
the laboratories of the collaborating investigators will also provide 
further training opportunities for predoctoral and postdoctoral fellows 
at both institutions. 
2) Consortium agreement between the applicant institution and the 
collaborating institution:  Collaborating institutions must document 
that the appropriate facilities, resources and research efforts will be 
committed for the investigators to accomplish the goals of the proposed 
research program.  Given that the CNS award is a result-oriented 
research mechanism, the investigators must clearly define the nature 
and the extent of the research collaboration such that the necessary 
administrative and fiscal considerations are fully explained in the 
application.  The CNS application should include letters from the 
applicant and collaborating institutions and relevant stakeholders that 
signify their intent to participate and to provide the necessary 
resources proposed in the application.  Before developing the 
application, review the NIH policy on consortium agreements in the NIH 
Grants Policy statement at

3) Research Areas: The NINDS is a leading supporter of scientific 
investigations into the causes, prevention, diagnosis, and treatment of 
neurological disorders and stroke.  NIDCD is the lead NIH Institute 
supporting research on the normal and disordered processes of hearing, 
balance, smell, taste, voice, speech and language. NIDA research 
includes a focus on the neurological impacts of drugs of abuse as well 
as associations between drugs of abuse, HIV and other co-morbid 
conditions. An application for a CNS award could include proposals for 
basic, clinical and/or translational neuroscience research in the areas 
including, but not limited to:

o Stroke and other cerebrovascular diseases and disorders;
o Episodic neurological states, such as epilepsy, chronobiology, 
circadian rhythms, and sleep;
o Tumors of the nervous system;
o Demyelinating and immunologically-mediated disorders of the nervous 
o Neuro-AIDS and other viral-associated diseases of the nervous system;
o Neuropsychiatric aspects of HIV/AIDS;
o Neuromuscular and peripheral nerve disorders;
o Fundamental neural processes;
o Sensory and motor processes subserving hearing, balance, smell, 
taste, speech, voice, somatosensation and movement;
o Pain;
o Neurodegenerative diseases and disorders;
o Trauma and injury to the nervous system;
o Repair and plasticity of the nervous system;
o Behavioral and cognitive neuroscience, including language processing;
o Neurogenetics; 
o Nervous system development; and
o Neurological impacts associated with drugs of abuse and the 
medical/mental/biological consequences and co-morbidity related to 
chronic drug use.

This PA will use the Minority Biomedical Research Support Thematic 
Project Grant (S11) funding mechanism.  The S11 mechanism is intended 
to promote increased faculty and interdepartmental collaboration 
through programs that focus on specific research themes or scientific 
disciplines at developing minority institutions.  These grants are 
intended to strengthen the biomedical research capabilities in defined 
areas and to attract other competent biomedical scientists through an 
improved research environment.
The applicant and collaborating investigator will be solely responsible 
for planning, directing, and executing the proposed project.  Awards 
are not renewable. This PA uses just-in-time concepts.  

An applicant may request a project period of up to 5 years and a budget 
for direct costs of up to $200,000 per year, which may include up to 
$75,000 for the collaborator (direct costs plus facilities and 
administrative costs).  Because the nature and scope of the proposed 
research will vary from application to application, it is anticipated 
that the size and duration of each award will also vary. Although the 
financial plans of the NINDS, NIDCD and NIDA provide support for this 
program, awards pursuant to this PA are contingent upon the 
availability of funds and the receipt of a sufficient number of 
meritorious applications.  


You may submit (an) application(s) if your institution has the 
following characteristics:

o For-profit or non-profit organizations 
o Public or private academic institution, such as universities and colleges that 
offer the Ph.D., M.D., and/or equivalent health professional degrees, at which 
more that 50 percent of the students enrolled are from racial or ethnic minority 
o Units of State and local governments
o Eligible agencies of the Federal government  
o Domestic 

Any individual with the skills, knowledge, and resources necessary to 
carry out the proposed research is invited to work with their 
institution to develop an application for support.  Individuals from 
underrepresented racial and ethnic groups as well as individuals with 
disabilities are encouraged to apply for NIH programs.   
1) Career stage appropriate for award:  The applicant investigator must 
have a doctoral degree in a basic or clinical neuroscience area.  The ideal 
applicant investigator should have completed two or more years of 
formal postdoctoral neuroscience research, and must hold an 
appointment equivalent to assistant professor at the applicant 
institution.  The applicant investigator must be a new investigator 
that is able to document the potential for excellence in research and 
provide evidence of the intent to develop a career in neuroscience 
research.  This evidence could be, for example, reflected in 
publication record, past attendance at scientific meetings, or a list 
of applications for small grants or mentored career development awards 
submitted to NIH, NSF, or non-federal organizations.  A new 
investigator is one who has not previously served as such on any PHS-
supported research project other than a small grant (R03), an Academic 
Research Enhancement Award (R15), an exploratory/developmental grant 
(R21), or certain research career awards directed principally to 
physicians, dentists, or veterinarians at the beginning of their 
research career (K01, K08, K22, K23).   Current or past recipients of 
Independent Scientist and other non-mentored career awards (K02 and 
K24) or project investigators on subprojects of program project or 
center grants (i.e. P20, P01, U54, etc.) are not considered new 
2) Collaborating Investigator: The collaborating investigator must be a 
grantee from a research-intensive institution that has current NIH or 
equivalent support to conduct neuroscience research (e.g., R01, P01).  
The collaborating investigator must be an individual holding a senior 
academic position, such as an associate professor or professor, and 
must have demonstrated research competency by virtue of competing 
successfully for current NIH or equivalent research grant support.
3) Citizenship:  The applicant investigator for an award must be a U.S. 
citizen or non-citizen national, or must have been lawfully admitted 
for permanent residence by the time of award.  Individuals admitted for 
permanent residence must be able to produce documentation of their 
immigration status such as an Alien Registration Receipt Card (I-551) 
or some other verification of legal admission as a permanent resident.  

4) Time and effort: The principal investigator must devote at least 50% 
effort and the collaborator must devote at least 10% effort to the 
proposed research project.  

5) Concurrent Applications: A candidate for a CNS award may not 
concurrently apply for any other PHS grant at the time of the CNS 
application submission, nor may there be another application pending 
funding. It is expected that a CNS award recipient will apply for PHS 
grant support during the performance period of award.

6) Change of Institution: CNS awards are not transferable to another 
individual but may be transferred to another eligible institution.  In 
the latter case, the awardee must contact the responsible NINDS Program 
Director to fully discuss the circumstances of the transfer, and must 
subsequently provide a written justification and rationale for the 
transfer.  The period of support requested can be no more than the time 
remaining within the existing original award project period.  Further, 
no transfer will be allowed for awards with less than six months 
remaining in the project period. 

We encourage your inquiries concerning this PA and welcome the 
opportunity to answer questions from potential applicants.  Inquiries 
may fall into three areas:  scientific/research, peer review, and 
financial or grants management issues:
o Direct your questions about scientific/research issues to:
Alfred W. Gordon, Ph.D.
Director, Office of Minority Health and Research
National Institute of Neurological Disorders and Stroke
The Neuroscience Center, Suite 2149
6001 Executive Blvd.
Bethesda, MD  20892-5929
Telephone:  (301) 496-3102
Fax:  (301) 594-5929

Daniel A. Sklare, Ph.D.
Program Director
Scientific Programs Branch
Division of Extramural Research
National Institute on Deafness and
 Other Communication Disorders
Executive Plaza South, Room 400C
6120 Executive Blvd., MSC-7180
Bethesda, MD 20892-7180
Tel: (301) 496-1804
Fax: (301) 402-6251

Ms. Jean Craft Comolli
Center on AIDS and Other Medical Consequences of Drug Abuse
National Institute on Drug Abuse 
The Neuroscience Center, Room 5194
6001 Executive Blvd.
Bethesda, MD 20892
Telephone: (301) 402-0630
Fax:  (301) 594-6566 or (301)480-4544

o Direct your questions about peer review issues to: 
Chief, Scientific Review Branch
National Institute of Neurological Disorders and Stroke
The Neuroscience Center, Suite 3208
6001 Executive Blvd.
Bethesda, MD 20892-9529 
Telephone:  (301) 496-9223
Fax:  (301) 402-0182
o Direct your questions about financial or grants management matters 
Ms. Dianna Jessee
Grants Management Branch 
National Institute of Neurological Disorders and Stroke 
The Neuroscience Center, Suite 3290
6001 Executive Blvd.
Bethesda, MD 20892-9537
Telephone:  (301) 496-7416
Fax:  (301) 402-0219

Ms. Sara Stone 
Chief, Grants Management Branch 
Division of Extramural Research
National Institute on Deafness and
 Other Communication Disorders
Executive Plaza South, Room 400C
6120 Executive Blvd.  MSC-7180
Bethesda, MD  20892-7180 
Telephone:  (301) 402-0909 
Fax:  (301) 402-1758 

Ms. Christine A. Kidd
Grants Management Branch
National Institute on Drug Abuse
The Neuroscience Center, Suite 3131
6001 Executive Blvd. 
Bethesda, MD 20892-9541
Telephone:  (301) 443-6710
Applications must be prepared using the PHS 398 research grant 
application instructions and forms (rev. 5/2001).  The PHS 398 is 
available at in 
an interactive format.  For further assistance contact GrantsInfo, 
Telephone (301) 710-0267, Email:
APPLICATION RECEIPT DATES: Applications submitted in response to this 
program announcement will be accepted at the standard application 
deadlines, which are available at  
Application deadlines are also indicated in the PHS 398 application kit.
SENDING AN APPLICATION TO THE NIH: Submit a signed, typewritten 
original of the application, including the checklist, and three signed 
photocopies in one package to:
Center for Scientific Review

ational Institutes of Health
6701 Rockledge Drive, Room 1040, MSC 7710
Bethesda, MD  20892-7710
Bethesda, MD  20817 (for express/courier service)
At the time of submission, two additional copies of the application 
must be sent to:

Alfred W. Gordon, Ph.D.
Director, Office of Minority Health and Research
National Institute of Neurological Disorders and Stroke
The Neuroscience Center, Suite 2149
6001 Executive Blvd.
Bethesda, MD  20892-5929
Telephone:  (301) 496-3102
Fax:  (301) 594-5929

APPLICATION PROCESSING: Applications must be received by or mailed on 
or before the receipt dates described at  The CSR 
will not accept any application in response to this PA that is 
essentially the same as one currently pending initial review unless the 
applicant withdraws the pending application.  The CSR will not accept 
any application that is essentially the same as one already reviewed.  
This does not preclude the submission of a substantial revision of an 
application already reviewed, but such application must include an 
Introduction addressing the previous critique.

Applications submitted for this PA will be assigned on the basis of 
established PHS referral guidelines.  An appropriate scientific review 
group convened in accordance with the standard NIH peer review 
procedures ( will evaluate 
applications for scientific and technical merit.  
As part of the initial merit review, all applications will:
o Receive a written critique
o Undergo a selection process in which only those applications deemed 
to have the highest scientific merit, generally the top half of 
applications under review, will be discussed and assigned a priority 
o Receive a second level review by the appropriate national advisory 
council or board
The goals of NIH-supported research are to advance our understanding of 
biological systems, improve the control of disease, and enhance health.  
In the written comments, reviewers will be asked to discuss the 
following aspects of your application in order to judge the likelihood 
that the proposed research will have a substantial impact on the 
pursuit of these goals: 
o Significance 
o Approach 
o Innovation
o Investigator
o Environment
The scientific review group will address and consider each of these 
criteria in assigning your application's overall score, weighting them 
as appropriate for each application.  Your application does not need to 
be strong in all categories to be judged likely to have major 
scientific impact and thus deserve a high priority score.  For example, 
you may propose to carry out important work that by its nature is not 
innovative but is essential to move a field forward.
(1) SIGNIFICANCE:  Does the study address an important problem? If the 
aims of the application are achieved, how do they advance scientific 
knowledge?  What will be the effect of these studies on the concepts or 
methods that drive this field?
(2) APPROACH:  Are the conceptual framework, design, methods, and 
analyses adequately developed, well integrated, and appropriate to the 
aims of the project, considering the applicant and collaborator 
research backgrounds and their respective contributions in the 
development of the research proposal? Are potential problem areas 
acknowledged and alternative tactics considered? The application must 
have scientific merit, but unlike a traditional research grant 
application, it must be evaluated in the context of the developmental 
goals and feasibility of the study.
(3) INNOVATION:  Does the project employ novel concepts, approaches or 
methods? Are the aims original and innovative?  Does the project 
challenge existing paradigms or develop new methodologies or 
(4) INVESTIGATOR: Are the Principal Investigator and collaborator 
appropriately trained and well suited to carry out this work, 
particularly the academic qualifications, neuroscience research 
experience, expertise and research productivity?  Is the work proposed 
appropriate to the experience level of the principal investigator and 
that of the other researchers?
(5) ENVIRONMENT:  Does the scientific environment in which the work 
will be done contribute to the probability of success?  Do the proposed 
experiments take advantage of unique features of the scientific 
environment and employ useful collaborative arrangements?  Is there 
evidence of institutional support?
ADDITIONAL REVIEW CRITERIA: In addition to the above criteria, your 
application will also be reviewed with respect to the following:
PROTECTIONS:  The adequacy of the proposed protection for humans, 
animals, or the environment, to the extent they may be adversely 
affected by the project proposed in the application.
INCLUSION:  The adequacy of plans to include subjects from both 
genders, all racial and ethnic groups (and subgroups), and children as 
appropriate for the scientific goals of the research.  Plans for the 
recruitment and retention of subjects will also be evaluated. (See 
Inclusion Criteria included in the section on Federal Citations, below)
DATA SHARING:  The adequacy of the proposed plan to share data. 

BUDGET:  The reasonableness of the proposed budget and the requested 
period of support in relation to the proposed research.
o The principal investigators will be at the beginning of their 
research careers.  Therefore, reviewers will consider the feasibility 
and promise for these investigators to gain scientific independence. 
Will the applicant investigator be able to produce the publications and 
preliminary data necessary to be competitive for a traditional research 
grant (e.g. R01) during the performance period of the award? Is a 
reasonable timeline for achieving these goals provided? 

o Is there a thematic research plan that documents an effective 
collaboration between the participating investigators? For example, is 
it clearly outlined which specific aims will be conducted in which 
laboratory, are the experiments conducted in each laboratory integral 
to the research program as a whole, will there be regular joint lab 
meetings, etc? Is a plan for receiving guidance and feedback from the 
collaborator on grantsmanship provided?

o Is there a proposed plan to enhance communications, cooperation, and 
scientific collaboration among the participating investigators, as well 
as the potential for the collaborative research effort to develop and 
promote competitive neuroscience research at the predominantly minority 
institution (e.g. shared research instrumentation and resources, 
exchange of research techniques, etc.)?
Applications submitted in response to a PA will compete for available 
funds with all other recommended applications.  The following will be 
considered in making funding decisions:  
o Scientific merit of the proposed project as determined by peer review
o Availability of funds 
o Relevance to program priorities
components involving Phase I and II clinical trials must include 
provisions for assessment of patient eligibility and status, rigorous 
data management, quality assurance, and auditing procedures.  In 
addition, it is NIH policy that all clinical trials require data and 
safety monitoring, with the method and degree of monitoring being 
commensurate with the risks (NIH Policy for Data Safety and Monitoring, 
NIH Guide for Grants and Contracts, June 12, 1998:  

policy of the NIH that women and members of minority groups and their 
sub-populations must be included in all NIH-supported clinical research 
projects unless a clear and compelling justification is provided 
indicating that inclusion is inappropriate with respect to the health 
of the subjects or the purpose of the research. This policy results 
from the NIH Revitalization Act of 1993 (Section 492B of Public Law 
All investigators proposing clinical research should read the AMENDMENT 
"NIH Guidelines for Inclusion of Women and Minorities as Subjects in 
Clinical Research - Amended, October, 2001," published in the NIH Guide 
for Grants and Contracts on October 9, 2001 
(; a 
complete copy of the updated Guidelines are available at   
The amended policy incorporates: the use of an NIH definition of clinical 
research; updated racial and ethnic categories in compliance with the new OMB 
standards; clarification of language governing NIH-defined Phase III clinical 
trials consistent with the new PHS Form 398; and updated roles and 
responsibilities of NIH staff and the extramural community.  The policy 
continues to require for all NIH-defined Phase III clinical trials that: a) all 
applications or proposals and/or protocols must provide a description of plans 
to conduct analyses, as appropriate, to address differences by sex/gender and/or 
racial/ethnic groups, including subgroups if applicable; and b) investigators 
must report annual accrual and progress in conducting analyses, as appropriate, 
by sex/gender and/or racial/ethnic group differences.
SUBJECTS: The NIH maintains a policy that children (i.e., individuals 
under the age of 21) must be included in all human subjects research, 
conducted or supported by the NIH, unless there are scientific and 
ethical reasons not to include them. This policy applies to all initial 
(Type 1) applications submitted for receipt dates after October 1, 
All investigators proposing research involving human subjects should 
read the "NIH Policy and Guidelines" on the inclusion of children as 
participants in research involving human subjects that is available at
policy requires education on the protection of human subject 
participants for all investigators submitting NIH proposals for 
research involving human subjects.  You will find this policy 
announcement in the NIH Guide for Grants and Contracts Announcement, 
dated June 5, 2000, at
HUMAN EMBRYONIC STEM CELLS (hESC): Criteria for federal funding of 
research on hESCs can be found at and at  
Only research using hESC lines that are registered in the NIH Human 
Embryonic Stem Cell Registry will be eligible for Federal funding (see   It is the responsibility of the applicant to 
provide the official NIH identifier(s)for the hESC line(s)to be used in 
the proposed research.  Applications that do not provide this 
information will be returned without review. 
The Office of Management and Budget (OMB) Circular A-110 has been 
revised to provide public access to research data through the Freedom 
of Information Act (FOIA) under some circumstances.  Data that are (1) 
first produced in a project that is supported in whole or in part with 
Federal funds and (2) cited publicly and officially by a Federal agency 
in support of an action that has the force and effect of law (i.e., a 
regulation) may be accessed through FOIA.  It is important for 
applicants to understand the basic scope of this amendment.  NIH has 
provided guidance at
Applicants may wish to place data collected under this PA in a public 
archive, which can provide protections for the data and manage the 
distribution for an indefinite period of time.  If so, the application 
should include a description of the archiving plan in the study design 
and include information about this in the budget justification section 
of the application. In addition, applicants should think about how to 
structure informed consent statements and other human subjects 
procedures given the potential for wider use of data collected under 
this award.
proposals for NIH funding must be self-contained within specified page 
limitations. Unless otherwise specified in an NIH solicitation, 
Internet addresses (URLs) should not be used to provide information 
necessary to the review because reviewers are under no obligation to 
view the Internet sites.   Furthermore, we caution reviewers that their 
anonymity may be compromised when they directly access an Internet 

HEALTHY PEOPLE 2010: The Public Health Service (PHS) is committed to 
achieving the health promotion and disease prevention objectives of 
"Healthy People 2010," a PHS-led national activity for setting priority 
areas. This PA is related to one or more of the priority areas. 
Potential applicants may obtain a copy of "Healthy People 2010" at
AUTHORITY AND REGULATIONS: This program is described in the Catalog of 
Federal Domestic Assistance Nos. 93.853, 93.173 and 93.279 and is not 
subject to the intergovernmental review requirements of Executive Order 
12372 or Health Systems Agency review.  Awards are made under 
authorization of Sections 301 and 405 of the Public Health Service Act 
as amended (42 USC 241 and 284) and administered under NIH grants 
policies described at 
and under Federal Regulations 42 CFR 52 and 45 CFR Parts 74 and 92. 

The PHS strongly encourages all grant recipients to provide a smoke-
free workplace and discourage the use of all tobacco products.  In 
addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits 
smoking in certain facilities (or in some cases, any portion of a 
facility) in which regular or routine education, library, day care, 
health care, or early childhood development services are provided to 
children.  This is consistent with the PHS mission to protect and 
advance the physical and mental health of the American people.

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS) - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.